Cart
sales@molnova.com
Home - Products - Others - Other Targets - Cholesteryl formate

Cholesteryl formate

CAS No. 4351-55-7

Cholesteryl formate( —— )

Catalog No. M37796 CAS No. 4351-55-7

Cholesteryl formate (3beta-Acetoxy-cholest-5-ene), the first compounds to be isolated from red algae, is a cholesteryl ester.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 48 Get Quote
10MG 67 Get Quote
25MG 104 Get Quote
50MG 154 Get Quote
100MG 223 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    Cholesteryl formate
  • Note
    Research use only, not for human use.
  • Brief Description
    Cholesteryl formate (3beta-Acetoxy-cholest-5-ene), the first compounds to be isolated from red algae, is a cholesteryl ester.
  • Description
    Cholesteryl formate (3beta-Acetoxy-cholest-5-ene), the first compounds to be isolated from red algae, is a cholesteryl ester.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    4351-55-7
  • Formula Weight
    414.66
  • Molecular Formula
    C28H46O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)OC=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • (Rac)-Naxifylline

    (Rac)-Naxifylline may be used to study congestive heart failure.

  • Simlukafusp alfa

    Simlukafusp alfa (FAP-IL2v) is a tumor-targeting immune cytokine, a human IgG1 antibody, with antitumor activity and immunostimulatory properties that potentiate in vitro and in vivo activity of therapeutic antibodies mediating antibody-dependent or T-cell-independent cytotoxicity (TDCC) and programmed death ligand 1 (PD-L1) checkpoint inhibition.

  • Vilobelimab

    Vilobelimab (CaCP-29, IFX-1), a monoclonal antibody targeting C5a, inhibits this pro-inflammatory complement component, which is pivotal in causing organ dysfunction.

Sign In Join Free